Crystal modification of 2,4-diamino-6-hydroxymethylpteridine hydrobromide
US5760229A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Feb 7, 1996 |
| Grant date | Jun 2, 1998 |
| Priority date | — |
| Expiry date | Feb 7, 2016 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D475/08
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
A novel crystal modification of the compound 2,4-diamino-6-hydroxymethylpteridine hydrobromide and a process for its preparation and its use for preparing methotrexate. The novel crystal modification of 2,4-diamino-6-hydroxymethylpteridine hydrobromide is distinguished in particular by the fact that only one equivalent of the brominating agent triphenylphosphine dibromide is needed for brominating the 6-hydroxymethyl group. No reaction with the amino groups in the 2 and 4 positions takes place. This facilitates the reaction to give 2,4-diamino-6-pteridinyl derivatives such as methotrexate.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.